0001493152-22-027554.txt : 20221004 0001493152-22-027554.hdr.sgml : 20221004 20221004161844 ACCESSION NUMBER: 0001493152-22-027554 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220930 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221004 DATE AS OF CHANGE: 20221004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 221291835 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 8-K 1 form8-k.htm
0001054102 false 0001054102 2022-09-30 2022-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 30, 2022

 

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

delaware   0-24249   22-2919486

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Morris Corporate Center 1, Building C

300 Interpace Parkway,

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(855) 776-6419

Registrant’s telephone number, including area code

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 30, 2022 (the “Transition Date”), Thomas Freeburg, the Chief Financial Officer of Interpace Biosciences, Inc. (the “Company”), resigned from his position as Chief Financial Officer and as an employee of the Company. Pursuant to a Severance and Consulting Agreement and General Release between the Company and Mr. Freeburg (the “Consulting Agreement”) effective September 30, 2022, Mr. Freeburg will provide certain consulting services to the Company, including finance and accounting services, as requested or deemed appropriate by the Company’s Chief Executive Officer and/or other senior management employees. Mr. Freeburg will continue to act as the Company’s principal financial officer during the Consulting Term, as defined below, until such time as the Company recruits a new Chief Financial Officer to replace Mr. Freeburg.

 

Pursuant to the Consulting Agreement, the Company agreed to pay Mr. Freeburg severance payments equal to $127,500 (which amount is equal to six months of Mr. Freeburg’s annual base salary in effect on the Transition Date), payable in semi-monthly installments in accordance with the Company’s payroll practices. On the Transition Date, Mr. Freeburg’s outstanding equity awards scheduled to vest during the 24-month period following the Transition Date accelerated and became fully vested on such date, and any stock options exercisable into a total of 50,000 shares of common stock of the Company that have vested on the Transition Date will remain exercisable until the 90th day following the Consulting Termination Date (as defined below). In addition, Mr. Freeburg remains eligible to continue participation in the Company’s health and dental benefit plans for the six-month period following the Transition Date, or if earlier, through the date Mr. Freeburg becomes eligible for other group health coverage in connection with new employment, provided he has properly and timely elected to continue such coverage under the Company’s plans. The Consulting Agreement includes general releases of claims by Mr. Freeburg in favor of the Company and certain Released Parties (as defined therein), and mutual non-disparagement obligations on Mr. Freeburg and on the Company. Mr. Freeburg remains subject to the Confidential Information, Non-Disclosure, Non-Competition, Non-Solicitation, and Rights to Intellectual Property Agreement, dated as of February 1, 2021, entered into with the Company. The Consulting Agreement commences on the Transition Date and terminates no earlier than January 30, 2023 and no later than March 30, 2023 (subject to extension upon mutual agreement by the parties) (the “Consulting Term”, and the termination date of the Consulting Term, the “Consulting Termination Date”). In consideration for Mr. Freeburg’s consulting services, the Company will pay Mr. Freeburg a monthly fee of $6,000 and reimburse reasonable expenses incurred by Mr. Freeburg in the performance of such consulting services, in accordance with the Company’s expense reimbursement policy. During the Consulting Term, Mr. Freeburg will not be required to devote, on average, more than twenty percent of his time (or approximately eight hours per week) in providing consulting services to the Company. In addition, during the Consulting Term, Mr. Freeburg may enter into other consulting agreements or arrangements or seek and obtain full-time employment or consulting assignments from other companies or individuals.

 

The foregoing summary of the Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Consulting Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
     
10.1   Severance and Consulting Agreement and General Release, dated September 30, 2022, by and between Interpace Biosciences, Inc. and Thomas Freeburg.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Interpace Biosciences, Inc.
     
  By: /s/ Thomas W. Burnell
  Name: Thomas W. Burnell
  Title: President and Chief Executive Officer

 

Date: October 4, 2022

 

 
 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

SEVERANCE AND CONSULTING AGREEMENT AND GENERAL RELEASE

 

This Severance and Consulting Agreement and General Release (this “Agreement” or this “Agreement and General Release”), dated September 30, 2022, is entered into by Thomas Freeburg (“Executive”) and Interpace Biosciences, Inc. (the “Company”). Executive and the Company are jointly referred to in this Agreement as the “Parties” and both individually referred to in this Agreement as a “Party.”

 

1. Termination of Employment. The Parties acknowledge and agree that Executive’s employment with the Company and its affiliates will terminate by the Company without cause on September 30, 2022 (the “Employment Termination Date”) and that such termination of employment will constitute a “separation from service” under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). Irrespective of whether Executive signs this Agreement, (a) to the extent unpaid, Company shall pay Executive on the first regular payroll date following the Employment Termination Date for Executive’s accrued salary and accrued and unused PTO days through the Employment Termination Date, which shall total twenty-four (24) days, and (b) Executive shall be entitled to retain possession of his laptop computer, monitor, cell phone and iPad. Executive’s participation in the Company’s group health insurance plan will end on the Employment Termination Date, and to the extent provided by COBRA and by the Company’s current group health insurance policies, Executive will be eligible to continue Executive’s group health insurance benefits at Executive’s own expense other than with regard to the first six months of benefits which will be at the Company’s expense. Upon the Employment Termination Date, (i) any of Executive’s outstanding equity awards that were scheduled to vest during the 24-month period following the Employment Termination Date shall accelerate and become fully vested as of such date, and (ii) any such equity awards that are stock options (totaling 50,000 shares of common stock) that are vested on the Employment Termination Date (including all of the accelerated awards referenced in paragraph 1(i) herein) shall remain exercisable through the 90th day following the Consulting Termination Date (as defined below) (or, if earlier, the stated term of the applicable stock option).

 

2. Consulting Services. During the Consulting Term (as defined below), Executive shall provide certain consulting services (the “Services”) to the Company, as the Company’s Chief Executive Officer and/or other senior management employees of the Company may from time to time request and deem appropriate, including, but not limited to finance and accounting services, which shall include the (a) review of the Company’s financial reporting and SEC filings and (b) Executive’s signature on the Form 10-Q for the period ending on September 30, 2022 and the certifications thereto, as permitted by United States Securities and Exchange Commission rules and regulations, the Sarbanes-Oxley Act of 2002, Company by-laws, policies and procedures, and any other laws, rules and regulations that pertain to Form 10-Q filings (collectively, “the 10-Q Signature Rules”). If the 10-Q Signature Rules do not permit executive to provide his signature on the Company’s Form 10-Q for the period ending on September 30, 2022 to be filed with the Securities and Exchange Commission, it will not be considered a breach or violation of this agreement by Executive, and all other terms and conditions of this agreement shall remain in full force and effect. Executive shall devote such time and attention to the business of the Company as is necessary to perform the Services hereunder, but in no event shall he be required to devote, on average, more than twenty percent (20%) of his time (or approximately eight (8) hours per week) during the Consulting Term in performing such Services. While working at a site other than the Company’s offices, Executive will be responsible for providing its own supplies and office equipment. Executive represents and warrants that Executive has the skill, expertise, and experience to perform the Services in accordance with all applicable laws.

 

 
 

 

i. In consideration of Executive’s expertise related to the Services, Executive’s acceptance of this Agreement, and of Executive’s performance of the Services as set forth herein, the Company shall pay Executive a monthly fee of $6,000. Invoices for Services (cash compensated) and expenses will be submitted by Executive to the Company on a regular but no less than weekly basis and shall clearly identify Executive’s business name, address, and Federal Tax ID Number. The Company will pay such invoices within 15 days upon receipt of invoice. The Company will not withhold any federal, state or local income, Social Security, unemployment or other taxes on account of payments to Executive hereunder, but will remit the full amount of such payments to Executive and report them on IRS Form 1099. Reasonable expenses incurred by Executive in the course of performing the Services shall be reimbursed by the Company upon receipt and submission of evidence satisfactory to the Company, of the incurrence and purpose of each such expense and otherwise in accordance with the Company’s expense substantiation policy. Any line item expense of more than $1,500 will need prior Company approval.

 

ii. It is understood and agreed that Executive’s performance of the Services are as an independent contractor and not an employee of the Company, and the manner and means of Executive’s provision of the Services will be under Executive’s direction and control. Neither Executive nor the Company shall make any commitments or create any obligations in the name of the other. Executive shall have no authority to bind the Company or assume any obligations or liabilities of any nature for or on behalf of the Company and Executive will not have, and will not represent to third parties as having, actual or apparent power or authority to do or take any action for or on behalf of the Company as its agent or representative. Neither the Company nor any the Company entity shall provide to Executive any employee benefits, including without limitation any medical, dental, pension, retirement, savings or insurance benefits which may be provided to employees of the Company or of any Company entity, except in connection with the severance benefits set forth in Section 3(ii). Executive agrees to timely deposit all taxes required to be paid with respect to fees paid to it for the performance of the Services, and will indemnify the Company from all claims, interest or penalties relating to taxes due with respect to the fees provided by the Company to Executive. If requested, Executive agrees to promptly complete and deliver to the Company and execute IRS form 4669 (Statement of Payments Received) with respect to any amount payable hereunder.

 

iii. The term of the Services (the “Consulting Term”) shall commence on the Employment Termination Date and shall terminate no earlier than four (4) months, but no later than six (6) months thereafter or upon such later date as may be mutually agreed upon by the Parties in writing (the date on which the Consulting Term terminates, the “Consulting Termination Date”). Notwithstanding the foregoing, (x) the Company may terminate the Consulting Term prior to the end of the Consulting Term immediately upon written notice of termination for Cause (as defined below); provided that the Company shall pay Executive’s fees through the date of delivery of such notice, and (y) the Consulting Term shall terminate automatically and without any written notice upon the death or disability of Executive which renders Executive incapable of performing Executive’s duties hereunder. For purposes of this Agreement, “Cause” shall mean Executive’s (i) gross negligence or willful misconduct in the performance of the Services; (ii) engagement in any felonious acts or other acts showing dishonesty or moral turpitude; or (iii) breach of any restrictive covenant set forth in any written agreement between Executive and the Company.

 

iv. The Company acknowledges and agrees that Executive may enter into other consulting agreements or arrangements with other companies or individuals during the Consulting Term and Executive may seek and obtain full-time employment or consulting assignments from other companies or individuals neither of which will impede or interfere with Executive’s ability to provide the Consulting Services hereunder.

 

1
 

 

3. Post-Termination Severance Benefits. If Executive: (i) timely signs, returns and does not revoke this Agreement pursuant to Section 10 below and (ii) complies fully with Executive’s obligations hereunder, which includes, without limitation, the subsequent execution and non-revocation of a Severance Agreement and General Release acceptable to the Company following the Consulting Termination Date (the “Post-Consulting Release”), then the Company will provide Executive with the following severance payments and benefits:

 

i. An amount equal to one hundred and twenty-seven thousand five hundred dollars ($127,500) (which amount, for the avoidance of doubt, is equal to six (6) months of Executive’s annual base salary in effect on the Employment Termination Date), payable in semi-monthly installments on the Company’s regularly scheduled payroll dates over a six-month period beginning on the first regular payroll date following the effective date of this Agreement.

 

ii. If Executive properly and timely elects to continue health and dental coverage under the Company’s plan in accordance with the continuation requirements of COBRA, payment for the cost of the premiums for such coverages for Executive and spouse for a six (6) month period following the Employment Termination Date, or if earlier, through the date on which Executive becomes eligible for other group health coverage in connection with new employment.

 

Executive understands and agrees that he is not entitled to any severance money or benefits, other than those offered in accordance with the terms of this Agreement. Executive further acknowledges that he in the event he fails to execute the Post-Consulting Release within 21 days of the Consulting Termination Date, Executive shall reimburse the Company for the severance payments and benefits paid to Executive as set forth in Section 11 below. The severance payments and benefits will commence on the first regular payroll date following the effective date of this Agreement.

 

4. 409A Compliance. The following rules shall apply, to the extent necessary, with respect to distribution of the payments and benefits, if any, to be provided to Executive under this Agreement. This Agreement is intended to comply with or be exempt from Section 409A of the Code (“Section 409A”) and the Parties hereto agree to interpret, apply and administer this Agreement in the least restrictive manner necessary to comply therewith and without resulting in any increase in the amounts owed hereunder by the Company. The severance payments and benefits pursuant to this Agreement shall begin only after the date of Executive’s “separation from service” which for purposes of this Agreement shall be the Employment Termination Date. Notwithstanding anything herein to the contrary, the Company shall have no liability to Executive or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.

 

5. Taxes. The Company may withhold from any amounts payable under this Agreement such federal, state or local income taxes as may be appropriate, except for the payments for consulting services under 2(i) .

 

 
 

 

6. Executive’s General Release of Claims. In exchange for the payments and benefits described in this Agreement, Executive knowingly and voluntarily releases the Company and its parent corporations, affiliates, subsidiaries, divisions, predecessors, insurers, successors and assigns, and their current and former employees, attorneys, officers, directors, shareholders, agents, representatives and employee benefit plans and programs and their administrators and fiduciaries (collectively referred to in this Agreement and General Release as the “Released Parties”), from any and all claims, known and unknown, resulting from anything which has happened up to the date Executive signs this Agreement, including any claim for attorneys’ fees, relating to or arising out of Executive’s employment with the Company. For purposes of this release, “Executive” includes Executive and his heirs and legal representatives.

 

Without limiting the release in the prior paragraph in any way, Executive expressly waives and releases all claims relating to or arising out of any conduct of the Released Parties with respect to Executive’s employment with the Company and/or any other aspect of Executive’s employment with the Company and Executive’s termination of employment, including, but not limited to all claims under:

 

  ● The Age Discrimination in Employment Act;
  ● The National Labor Relations Act;
  ● Title VII of the Civil Rights Act;
  ● Sections 1981 through 1988 of Title 42 of the United States Code;
  ● The Employee Retirement Income Security Act (except for any vested benefits under any tax qualified benefit plan);
  ● The Genetic Information Nondiscrimination Act;
  ● The Immigration Reform and Control Act;
  ● The Americans with Disabilities Act;
  ● The Occupational Safety and Health Act;
  ● The Workers Adjustment and Retraining Notification Act;
  ● The Fair Credit Reporting Act;
  ● The Family and Medical Leave Act;
  ● The Equal Pay Act;
  ● The Uniformed Services Employment and Reemployment Rights Act;
  ● Employee Polygraph Protection Act;
  ● The Employee (whistleblower) civil protection provisions of the Corporate and Criminal Fraud Accountability Act (Sarbanes-Oxley Act);
  ● The New Jersey Law Against Discrimination;
  ● The New Jersey Civil Rights Act;
  ● The New Jersey Family Leave Act;
  ● The Millville Dallas Airmotive Plant Job Loss Notification Act;
  ● The New Jersey Conscientious Employee Protection Act;
  ● The New Jersey Equal Pay Law;
  ● The New Jersey Occupational Safety and Health Law;

 

 
 

 

  ● The New Jersey Smokers’ Rights Law;
  ● The New Jersey Genetic Privacy Act;
  ● The New Jersey Fair Credit Reporting Act;
  ● The New Jersey Statutory Provision Regarding Retaliation/Discrimination for Filing A Workers’ Compensation Claim;
  ● other federal, state or local law equal employment opportunity or other laws, regulations, or ordinances;
  ● breach of contract; quasi contract; negligence; interference with contract/business advantage; fraud; defamation; intentional infliction of emotional distress;
  ● common law wrongful discharge from employment; and
  ● any other duty or obligation of any kind or description to the fullest extent permissible by law.

 

Executive does not waive or release: (1) his right to enforce or challenge this Agreement and General Release; (2) any vested rights which Executive may have under any employer sponsored benefit plan; (3) the right to file any unwaivable charge or complaint with a government administrative agency (although Executive does waive and release any right to recover damages in connection with any such charge or complaint relating to anything which has happened up to the date Executive signs this Agreement); (4) rights or claims which cannot lawfully be released; (5) any right to defense or indemnification based upon Executive’s past conduct within the course and scope of Executive’s duties for the Company that Executive may have whether based on Company bylaws, state law, or insurance policy; and (6) rights or claims arising after the date Executive signs this Agreement.

 

Executive represents that as of the date he signs this Agreement and General Release, he is unaware of any work related illness or injury. Executive also acknowledges and agrees that he has fully and timely received all wages, overtime compensation, bonuses, commissions, benefits, and/or other amounts due in connection with his employment with and termination from the Company.

 

Executive represents that, as of the date he signs this Agreement, he has not filed any charge, complaint, claim, or action with any court, organization, governmental entity, or administrative agency against the Company, or any of the other Released Parties.

 

Notwithstanding any other provision herein, nothing in this Agreement and General Release is intended in any way to limit Executive’s right or ability to initiate or participate in any investigation or proceeding conducted by any federal, state or local agency, including the U.S. Equal Employment Opportunity Commission (“EEOC”), the National Labor Relations Board, the Department of Labor, the Department of Justice and/or the U.S. Securities and Exchange Commission (“SEC”), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. Notwithstanding the foregoing, Executive agrees to waive any right to recover monetary damages in any suit, complaint, charge or other proceeding filed by Executive or anyone else on Executive’s behalf.

 

 
 

 

7. Restrictive Covenants and Return of Property. Executive represents that Executive has not divulged any proprietary or confidential information of the Company and will remain subject to the confidentiality and other restrictive covenants contained in the Confidential Information, Non-Disclosure, Non-Competition, Non-Solicitation, and Rights to Intellectual Property Agreement previously entered into by Executive in favor of the Company, dated as of February 1, 2021 (the “Confidentiality Agreement”), which is incorporated by reference herein. Executive represents that Executive shall return all of the Company’s property, documents, and/or any confidential or proprietary information in Executive’s possession or control by the Consulting Termination Date. Executive also agrees that Executive is in possession of all of Executive’s property that Executive had at the Company’s premises and that the Company is not in possession of any of Executive’s property.

 

8. Confidentiality of this Agreement. Executive shall not disclose or cause to be disclosed the terms of this Agreement to any person (other than Executive’s spouse or domestic/civil union partner, attorney and tax advisor), except pursuant to a lawful subpoena or as otherwise permitted by law. This provision is not intended to otherwise restrict Executive’s legal right to discuss the terms and conditions of Executive’s employment.

 

9. Non-Disparagement. Executive acknowledges and agrees that he will not make any negative comments or disparaging remarks, in writing, orally or electronically, about the Company or any other Released Parties and their respective products and services. The Company shall instruct its officers and directors to not make any negative comments or disparaging remarks, in writing, orally or electronically, about Executive. Notwithstanding the foregoing, in no event will any legally required disclosure be deemed to violate this paragraph, regardless of the content of such disclosure or the nature of such action.

 

10. ADEA Release. Executive specifically waives and releases the Company from all claims Executive may have as of the date Executive signs this Agreement regarding claims or rights arising under the Age Discrimination in Employment Act of 1967, as amended, 29 U.S.C § 621 et al. (“ADEA”), including the Older Workers Benefit Protection Act of 1990. This paragraph does not waive rights or claims that may arise under the ADEA after the date Executive signs this Agreement. Executive acknowledges the payments and other consideration that are being provided to Executive hereunder are of significant value and are in addition to what Executive otherwise would be entitled. The Company hereby advises Executive in writing to consult an attorney prior to signing this Agreement. Executive is being given a period of at least twenty-one (21) days within which to review and consider this Agreement before signing it, though Executive may sign earlier. Executive cannot sign this Agreement prior to Executive’s Employment Termination Date. Following execution of this Agreement, Executive shall have the right to revoke it for seven (7) days (“Revocation Period”). This Agreement shall not be effective and enforceable until after the Revocation Period has expired without this Agreement being revoked. To revoke this Agreement, Executive must send a letter to the Company at the attention of the Chairman of the Board at 300 Interpace Parkway, Building C, 1st Floor, Parsippany, NJ 07054. The letter must be received within seven (7) days of Executive’s execution of this Agreement. If the seventh day is a Sunday or federal holiday, then the letter must be received by the following business day. If Executive revokes this Agreement on a timely basis, Executive shall not be eligible for the consulting payments and post-termination severance benefits set forth in Sections 2 and 3, respectively.

 

 
 

 

11. Remedies for Breach. If the Company, in its sole discretion, determines that Executive has breached, or is about to breach any provision of this Agreement, including, without limitation, the Confidentiality Agreement, or the failure of Executive to execute and not revoke the Post-Consulting Release, the Company may immediately cease any payments pursuant to this Agreement, and Executive shall be required to reimburse the Company for all amounts paid to Executive under this Agreement, except for the first payment made under Section 3(i) of this Agreement and the first monthly fee under Section 2(i).

 

12. Governing Law and Interpretation. This Agreement shall be interpreted in accordance with the laws of the State of Delaware without regard to principles of conflicts of laws.

 

13. Severability. Should any provision or part of any provision of this Agreement be declared illegal, unenforceable, or ineffective in any legal forum, that provision or part of that provision shall immediately become null and void, but the rest of this Agreement and General Release will remain in full force and effect.

 

14. No Admission of Wrongdoing and Attorneys’ Fees. Neither Party, by signing this Agreement, admits to any wrongdoing or liability to the other. Both Executive and the Company deny any wrongdoing or liability. The Parties shall each bear their own attorneys’ fees and/or expenses incurred in connection with this Agreement and no Party shall be deemed a prevailing Party for any purpose.

 

15. Indemnification/Acknowledgment. The Company hereby agrees to indemnify and hold Executive harmless, including attorneys’ fees, for all conduct of Executive within the scope of his employment or consultancy whether as an employee or consultant including to the fullest extent provided under the Company’s by-laws and insurance policies, and as provided to other executives and/or board members. The Company also acknowledges and represents that Executive has not played any meaningful role in deciding or determining Company pricing, reimbursement, billing and/or collection decisions or policies during his term of employment.

 

15. Amendment. This Agreement may not be modified, altered or changed except in writing and signed by both Executive and the Company.

 

 
 

 

16. Entire Agreement. This Agreement and General Release sets forth the entire agreement between Executive and the Company with respect to the subject matter hereof. This Agreement and General Release supersedes and replaces any and all prior agreements or understandings between Executive and the Company, except the Confidentiality, Non-Competition, and Non-Solicitation Agreement which shall survive and continue to remain in full force and effect. Executive acknowledges that Executive has not relied on any representations, promises, or agreements of any kind made to Executive in connection with Executive’s decision to accept this Agreement and General Release, except for those set forth in this Agreement and General Release.

 

17. Representation by Counsel. Executive acknowledges that he has had ample time and opportunity to consult with the attorney of his choice in connection with his execution of this Agreement if he elected to do so; that he has carefully read and fully understands all of the provisions of this Agreement; and that he has had adequate time to review this Agreement and the General Release contained in this Agreement.

 

18. Agreement is Joint Product. The Parties acknowledge that this Agreement is a joint product and shall not be construed for or against any Party on the ground of sole authorship. This Agreement may be executed in multiple originals, each of which shall be considered an original instrument, but all of which shall constitute one agreement, and shall bind the Parties hereto and their successors, heirs, assigns, and legal representatives.

 

19. Counterparts. This Agreement may be executed in counterparts, each being deemed an original document. This Agreement shall be binding upon the execution and delivery by facsimile or email by all Parties to this Agreement as if the same were manually executed and delivered by such Parties. The Parties agree to promptly deliver to each other original executed counterparts of this Agreement.

 

20. Assignment. Neither Party may assign such Party’s rights or obligations hereunder without the prior written consent of the other Party.

 

21. Headings. Headings contained in this Agreement are for convenience of reference only and are not intended, and shall not be construed, to modify, define, limit, or expand the intent of the Parties as expressed in this Agreement, and they shall not affect the meaning or interpretation of this Agreement.

 

22. No Waiver. No waiver by any Party hereto of any breach of this Agreement by any other Party shall operate or be construed as a waiver of any other or subsequent breach.

 

[signature page follows]

 

 
 

 

EXECUTIVE
     
/s/ Thomas Freeburg   9/30/2022
Thomas Freeburg   Date
     
Interpace Biosciences, Inc.    
     
/s/ Thomas W. Burnell   9/30/2022
Thomas W. Burnell   Date
President and Chief Executive Officer    

 

 

 

 EX-101.SCH 3 idxg-20220930.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 idxg-20220930_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 5 idxg-20220930_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 30, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 30, 2022
Entity File Number 0-24249
Entity Registrant Name INTERPACE BIOSCIENCES, INC.
Entity Central Index Key 0001054102
Entity Tax Identification Number 22-2919486
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Morris Corporate Center 1
Entity Address, Address Line Two Building C
Entity Address, Address Line Three 300 Interpace Parkway
Entity Address, City or Town Parsippany
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07054
City Area Code (855)
Local Phone Number 776-6419
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not Applicable
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001054102 2022-09-30 2022-09-30 iso4217:USD shares iso4217:USD shares 0001054102 false 8-K 2022-09-30 INTERPACE BIOSCIENCES, INC. DE 0-24249 22-2919486 Morris Corporate Center 1 Building C 300 Interpace Parkway Parsippany NJ 07054 (855) 776-6419 Not Applicable false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://interpace.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm idxg-20220930.xsd idxg-20220930_lab.xml idxg-20220930_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "idxg-20220930_lab.xml" ] }, "presentationLink": { "local": [ "idxg-20220930_pre.xml" ] }, "schema": { "local": [ "idxg-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "IDXG", "nsuri": "http://interpace.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-30to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://interpace.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-30to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-027554-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-027554-xbrl.zip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c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